CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 356 enrolled
Drug / intervention
MRI/MRS +1 moreprocedure
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00043017
NCT00043017Phase 2Completed
CompareCT.gov

Contrast-Enhanced Breast MRI For Evaluation Of Patients Undergoing Neoadjuvant Treatment For Locally-Advanced Breast Cancer (I-SPY 1/ACRIN 6657)

American College of Radiology Imaging Network·interventional·Posted Jan 27, 2003·Updated Oct 9, 2013

In Brief

A Phase 2 clinical trial evaluating MRI/MRS and gadopentetate dimeglumine for Breast Cancer. Completed, enrolled 356 participants across 11 sites.

Detailed Summary

RATIONALE: Diagnostic procedures such as magnetic resonance imaging (MRI) may help determine the effectiveness of chemotherapy in killing breast cancer and allow doctors to plan more effective treatment. PURPOSE: Diagnostic trial to study the effectiveness of MRI in monitoring tumor response in women who are receiving chemotherapy for stage III breast cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 2CompletedFinished
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 27, 2003
Enrollment StartMay 1, 2002
Primary CompletionMay 1, 2005
Study CompletionMar 1, 2011
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 23.4 years ago

Interventions

MRI/MRSprocedure

Serial MRI studies evaluated for prognostic properties related to therapeutic response.

gadopentetate dimeglumineradiation

Imaging agent used for contrast enhancement in each of the MRIs.